We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Albany Announces Drug Discovery Research Collaboration with Bristol-Myers Squibb
News

Albany Announces Drug Discovery Research Collaboration with Bristol-Myers Squibb

Albany Announces Drug Discovery Research Collaboration with Bristol-Myers Squibb
News

Albany Announces Drug Discovery Research Collaboration with Bristol-Myers Squibb

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Albany Announces Drug Discovery Research Collaboration with Bristol-Myers Squibb"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Albany Molecular Research, Inc. (AMRI) has entered into a two-year natural products based drug discovery collaboration with Bristol-Myers Squibb Company.

Under the terms of the agreement, AMRI will test samples from its natural product hit seeking collections against multiple drug targets, with the goal of identifying hit compounds with desired biological activity in a potential range of therapeutic areas.

According to AMRI, it may provide follow-up medicinal chemistry hit-to-lead optimization, biocatalysis or chemical synthesis support on compounds of interest in addition to Bristol-Myers Squibb.

The collaboration includes an upfront payment, research funding and opportunities for AMRI to receive payments based on the specific development and commercialization goals.

AMRI would also receive royalty payments on sales of commercial products that result from the collaboration.

“We are pleased to announce this natural products relationship with Bristol-Myers Squibb,” said AMRI Chairman, President and Chief Executive Officer Thomas E. D'Ambra, Ph.D.

“This collaboration draws on AMRI’s breadth of drug discovery technologies, from our diverse collection of natural products and high throughput screening, to world class hit-to-lead optimization.”

This is AMRI’s second collaboration with Bristol-Myers Squibb. The two companies have a separate, ongoing collaboration into new treatments for disorders of the central nervous system.

Advertisement